Short answer
Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K current report with the SEC on April 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Jeff Knight resigned as Chief Development and Operating Officer effective April 10, 2026.
Crinetics Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jeff Knight resigned as Chief Development and Operating Officer effective April 10, 2026
- One-year consulting agreement preserves Knight’s operational and clinical development support through April 10, 2027
- Consulting compensation: $400 per hour, capped at 20 hours monthly, plus pre-approved expenses
- Unvested RSUs and options forfeited; vested options remain exercisable through three months after consulting ends
- Transition includes mutual protections: Knight’s release of claims and continued company indemnification during consulting period
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Crinetics Pharmaceuticals, Inc. 8-K filings
Get the next CRNX 8-K as it lands
Follow CRNX for push alerts, or ask the research agent what this filing means.